Join
Live feed
·
PRReleasevia Quantisnow
Oncolytics Biotech Inc. logo

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ONCY· Oncolytics Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONCY (Oncolytics Biotech Inc.) and more on Quantisnow.

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting | Quantisnow